mRNA Vaccines and Therapeutics Market Market Size, Share, Growth, and Industry Analysis, By Types (COVID Vaccines, Infectious Disease Vaccines, Cancer Vaccines, Autoimmune Diseases, Others), Applications (Hospitals & Clinics, Research Organization, Others), and Regional Insights and Forecast to 2035
Buy Now - USD 3,250
mRNA Vaccines and Therapeutics Market Size
The Global mRNA Vaccines and Therapeutics Market size stood at USD 5.95 Billion in 2025 and rose to USD 6.46 Billion in 2026, reaching around USD 7.02 Billion in 2027, with projected revenue expected to reach USD 13.71 Billion by 2035, growing at a CAGR of 8.71% during 2026–2035. Market expansion is driven by advancements in biotechnology and vaccine development. Nearly 54% of investments are directed toward infectious disease research, while over 43% support oncology applications, strengthening long-term growth.
In the U.S., mRNA Vaccines and Therapeutics Market increasing focus on pandemic preparedness, advancements in mRNA technology, and growing investment in biotechnology R&D are key drivers. Rising awareness of mRNA therapeutics for cancer and rare diseases also accelerates market growth.
The mRNA vaccines and therapeutics market has revolutionized the healthcare industry by providing solutions for diseases previously considered difficult to treat. Over 400 clinical trials involving mRNA technology are currently underway worldwide. The market has expanded rapidly since the first mRNA vaccine approvals, with over 20 mRNA vaccines and therapeutics in late-stage clinical trials, focusing on applications like cancer, HIV, and rare genetic conditions. This growth is fueled by advancements in delivery systems, such as lipid nanoparticles (LNPs), which are crucial for enhancing the stability and efficiency of mRNA therapeutics.
Key Findings
- Market Size (mRNA Vaccines and Therapeutics): Valued at USD 5.95 Billion in 2025, expected to reach USD 6.46 Billion in 2026 and USD 13.71 Billion by 2035, expanding at a CAGR of 8.71%.
- Growth Drivers: Expanding vaccine R&D (≈37%), government immunization initiatives (≈29%), and cancer vaccine pipeline growth (≈22%).
- Trends: Personalized mRNA vaccines, lipid nanoparticle advancements, and global scale-up of vaccine manufacturing.
- Key Players: BioNTech, AstraZeneca, Pfizer, Intellia Therapeutics, CRISPR Therapeutics, Boehringer Ingelheim, Sangamo, GlaxoSmithKline, Bayer, Moderna.
- Applications: "Hospitals, Clinics, and Research Organizations".
mRNA Vaccines and Therapeutics Market Trends
The mRNA vaccines and therapeutics market is experiencing a surge in innovation and adoption, driven by growing applications in diverse medical fields. To date, over 50 mRNA-based products are undergoing clinical trials, targeting diseases such as influenza, melanoma, and cystic fibrosis. Among these, cancer therapeutics hold a significant share, with personalized mRNA-based vaccines showing promising results in phase II trials. In infectious diseases, next-generation mRNA vaccines aim to address global health issues like tuberculosis and malaria.
Technological advancements are reshaping the market, with lipid nanoparticle (LNP) technology leading the charge in enhancing delivery systems. Research into thermostable mRNA formulations is addressing cold-chain logistics challenges, making mRNA vaccines more accessible in low-resource regions. Moreover, partnerships between pharmaceutical companies and biotech firms have accelerated product development, with over 100 collaborations reported in the past three years.
Geographically, North America leads the market due to its robust R&D ecosystem, while Europe follows closely with significant investments in biotech innovation. The Asia-Pacific region is emerging as a strong contender, with countries like China and India ramping up manufacturing capabilities. Governments worldwide are increasing funding for mRNA technology, with investments in the billions, further fueling market growth. As more companies enter the competitive landscape, innovation in cost efficiency and expanded applications is becoming a key focus.
mRNA Vaccines & Therapeutics Market Dynamics
Rising demand for innovative therapeutics
With 10M+ new cancer cases annually and persistent infectious disease threats, mRNA platforms enable rapid, specific interventions. 50+ clinical-stage products and strong public funding post-COVID support continued pipeline expansion and broader indications.
Expansion in personalized medicine
Genomics enables individualized mRNA therapies, notably tumor mutation–targeted vaccines showing promise in phase II. APAC’s growing research capacity and cost advantages position the region as a hub for personalized mRNA solutions and trials.
RESTRAINTS
High costs of development and manufacturing
LNP systems, specialized enzymes, and cGMP facilities elevate costs; stringent regulation and cold-chain logistics (driving ~20% wastage in low-resource settings) further restrain access and scale-up.
CHALLENGE
Limited infrastructure for large-scale production
Sophisticated facilities and talent are scarce, especially in emerging economies housing 60%+ of the population. Concentrated capacity creates supply bottlenecks and dependency on a few manufacturers.
Segmentation Analysis
The mRNA vaccines and therapeutics market is segmented based on type and application, offering a detailed understanding of its diverse landscape. By type, the market includes COVID vaccines, infectious disease vaccines, cancer vaccines, autoimmune diseases, and others. By application, the market spans hospitals and clinics, research organizations, and other settings. This segmentation highlights the breadth of mRNA technology's impact across different medical needs and institutional uses.
By Type
- COVID Vaccines: COVID-19 mRNA vaccines represent the largest segment due to their groundbreaking success in combating the pandemic. More than 13 billion COVID vaccine doses have been administered globally, with mRNA vaccines accounting for a significant portion. Leading vaccines from Pfizer-BioNTech and Moderna showcased up to 95% efficacy, setting a benchmark for future mRNA-based vaccines.
- Infectious Disease Vaccines: The segment for infectious disease vaccines is expanding as mRNA technology targets diseases like influenza, Zika virus, and malaria. Over 20 candidates are in clinical trials to address these diseases, aiming to improve global health outcomes. This segment is particularly crucial for low-resource regions where infectious diseases remain a significant burden.
- Cancer Vaccines: Cancer mRNA vaccines are gaining momentum with personalized approaches that stimulate the immune system to attack tumor cells. Over 30 mRNA-based cancer vaccine candidates are in clinical trials, with some targeting melanoma and other solid tumors showing promising efficacy. These advancements could revolutionize cancer treatment in the coming years.
- Autoimmune Diseases: Autoimmune disease therapeutics using mRNA are in the early stages of development. These treatments aim to modulate the immune system to prevent self-targeting responses. Diseases like multiple sclerosis and rheumatoid arthritis are being studied, offering hope for a new class of effective treatments.
- Others: Other applications include mRNA therapeutics for genetic disorders like cystic fibrosis and rare enzyme deficiencies. These innovations showcase the versatility of mRNA technology in addressing a wide range of medical challenges, with ongoing research further expanding the scope.
By Application
- Hospitals & Clinics: Hospitals and clinics represent a primary application segment for mRNA vaccines and therapeutics. Over 80% of COVID-19 vaccines were administered through healthcare facilities, emphasizing their critical role. Additionally, the adoption of mRNA-based cancer vaccines is expected to grow within oncology departments in hospitals.
- Research Organizations: Research organizations play a vital role in advancing mRNA technology. Over 400 clinical trials involving mRNA vaccines and therapeutics are being conducted globally, many spearheaded by research institutes and universities. This segment is essential for driving innovation and exploring new applications for mRNA.
- Others: Other application areas include pharmaceutical companies and contract manufacturing organizations (CMOs) that focus on large-scale production and distribution. These entities are critical in meeting the growing demand for mRNA vaccines and therapeutics, especially in regions with limited manufacturing capabilities.
mRNA Vaccines and Therapeutics Market Regional Outlook
The mRNA vaccines and therapeutics market demonstrates significant regional variations driven by differences in healthcare infrastructure, research capabilities, and government support. North America and Europe lead in innovation and adoption due to strong R&D ecosystems, while Asia-Pacific is emerging as a key manufacturing hub. The Middle East and Africa are witnessing growing investments to enhance accessibility, though challenges persist in infrastructure. Each region’s market trajectory is shaped by its unique strengths and opportunities.
North America
North America dominates the mRNA vaccines and therapeutics market, supported by advanced healthcare systems and substantial investments in biotechnology. The United States is home to major players like Moderna and Pfizer-BioNTech, which developed the first mRNA COVID-19 vaccines. Over 70% of the region’s population has received at least one dose of a COVID-19 vaccine, reflecting high adoption rates. The U.S. also leads in clinical trials, with over 200 mRNA-based studies underway, targeting diseases like cancer and autoimmune disorders. Canada is actively expanding its vaccine production capabilities, focusing on domestic manufacturing to reduce reliance on imports.
Europe
Europe is a significant player in the mRNA vaccines and therapeutics market, driven by strong research collaborations and government initiatives. Germany is at the forefront, being the home base for BioNTech, a pioneer in mRNA technology. The European Medicines Agency (EMA) has approved multiple mRNA vaccines, supporting rapid distribution across member states. By mid-2023, over 80% of the adult population in the European Union had been vaccinated against COVID-19, with mRNA vaccines comprising a majority of doses. The region is also investing in developing cancer and infectious disease therapeutics, with the U.K. and France making significant strides in clinical research.
Asia-Pacific
Asia-Pacific is emerging as a critical region for the mRNA vaccines and therapeutics market, thanks to its growing manufacturing capabilities and rising demand for advanced healthcare solutions. China has significantly increased its investments in mRNA research, with several domestic companies developing COVID-19 and cancer vaccines. India has also entered the mRNA landscape, with initiatives to produce affordable vaccines for low- and middle-income countries. Japan and South Korea are key contributors to R&D, focusing on personalized medicine and rare disease therapeutics. The region accounted for nearly 30% of global vaccine production in 2022, showcasing its potential to meet international demand.
Middle East & Africa
The Middle East and Africa are gradually adopting mRNA vaccines and therapeutics, supported by global initiatives to improve healthcare access. South Africa has established a facility to produce mRNA COVID-19 vaccines locally, aiming to reduce dependency on imports. In the Middle East, countries like the UAE and Saudi Arabia are investing in biotechnology to diversify their economies and improve healthcare outcomes. Despite these advancements, the region faces challenges in infrastructure and skilled workforce availability. Over 40% of the population in low-income countries in this region remains unvaccinated, highlighting the need for further investments in accessibility and education.
List of Key mRNA Vaccines and Therapeutics Market Companies Profiled
- BioNTech
- AstraZeneca Plc
- Pfizer
- Intellia Therapeutics
- CRISPR Therapeutics
- Boehringer Ingelheim
- Sangamo Therapeutics
- GlaxoSmithKline
- Bayer Group
- Moderna
Top Companies with Highest Market Share
- Pfizer: Holds an estimated 35% share of the mRNA vaccines market, largely due to the success of its COVID-19 vaccine developed in partnership with BioNTech.
- Moderna: Accounts for approximately 30% of the market, driven by its pioneering work in mRNA-based vaccine and therapeutic innovations.
Technological Advancements
Technological advancements are revolutionizing the mRNA vaccines and therapeutics market, significantly enhancing efficiency and broadening applications. Lipid nanoparticles (LNPs) have become the gold standard for delivering mRNA payloads, ensuring stability and targeted delivery. Over 90% of current mRNA vaccines use LNPs, demonstrating their critical role. Thermostable mRNA formulations are another breakthrough, addressing cold-chain storage challenges. For instance, recent advancements have extended vaccine shelf life up to 12 months at standard refrigeration temperatures.
Artificial intelligence (AI) and machine learning (ML) are transforming drug discovery and optimization. BioNTech has successfully utilized AI for personalized cancer vaccine development, significantly reducing research timelines. In addition, mRNA sequence optimization has improved protein expression efficiency by over 50%, making treatments more effective. Bioreactor technologies for large-scale production have also advanced, enabling facilities to produce billions of doses annually, as evidenced during the COVID-19 pandemic. These advancements collectively position the market for sustained growth and innovation.
NEW PRODUCTS Development
New product development is accelerating in the mRNA vaccines and therapeutics market, targeting diverse medical conditions. Moderna and BioNTech are leading the charge, with over 10 mRNA-based vaccines for non-COVID diseases in their pipeline. For instance, Moderna’s mRNA-4157, a personalized cancer vaccine for melanoma, has shown an impressive 44% reduction in the risk of recurrence or death in clinical trials.
Pfizer and BioNTech have also developed a combination mRNA vaccine for COVID-19 and influenza, which entered clinical trials in 2023. Additionally, mRNA-based therapies targeting genetic diseases, such as cystic fibrosis and sickle cell anemia, are in early-stage development. Intellia Therapeutics is working on gene-editing applications using CRISPR-Cas9 technology integrated with mRNA, opening new avenues for treating rare genetic disorders. These innovations reflect the rapid expansion of mRNA’s therapeutic scope beyond infectious diseases.
Recent Developments
- Combination Vaccines – Pfizer and BioNTech initiated clinical trials for a dual COVID-19 and flu mRNA vaccine in late 2023, aiming for broader immunization coverage.
- Cancer Vaccine Success – Moderna’s personalized cancer vaccine, mRNA-4157, demonstrated a 44% reduced risk of recurrence in melanoma patients in phase II trials.
- CRISPR Integration – Intellia Therapeutics advanced its gene-editing approach, utilizing mRNA for in vivo applications, with promising early results in treating transthyretin amyloidosis.
- Thermostable Formulations – Research into thermostable mRNA vaccines has extended product shelf life to up to 12 months under standard refrigeration conditions.
- Manufacturing Expansion – BioNTech announced a new manufacturing facility in Singapore in 2023, boosting regional production capacity by over 100 million doses annually.
REPORT COVERAGE
The report on the mRNA vaccines and therapeutics market provides a comprehensive analysis of trends, opportunities, and challenges influencing the industry. It covers detailed segmentation by type, application, and region, highlighting the growing adoption of mRNA technology in treating infectious diseases, cancer, and rare genetic conditions. The report profiles key players, including Pfizer, Moderna, and BioNTech, detailing their contributions and innovations in the field.
It examines technological advancements such as lipid nanoparticles (LNPs) and thermostable formulations, which have expanded the usability and accessibility of mRNA vaccines. Regional analysis emphasizes North America and Europe as dominant markets, with Asia-Pacific emerging as a key manufacturing hub. The report also highlights emerging applications in personalized medicine and collaborations between biotech companies and research organizations.
Additionally, the report tracks recent developments, such as combination mRNA vaccines and advances in gene-editing technologies. It underscores the industry's dynamic nature, offering insights into the competitive landscape, production capabilities, and future growth potential, providing a valuable resource for stakeholders aiming to capitalize on market opportunities.
"mRNA Vaccines and Therapeutics Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 5.95 Billion in 2026 |
|
|
Market Size Value By |
USD 13.71 Billion by 2035 |
|
|
Growth Rate |
CAGR of 8.71% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation 
Download FREE Sample
|
||
Frequently Asked Questions
-
What value is the mRNA Vaccines and Therapeutics Market expected to touch by 2035?
The global mRNA Vaccines and Therapeutics Market is expected to reach USD 13.71 Billion by 2035.
-
What CAGR is the mRNA Vaccines and Therapeutics Market expected to exhibit by 2035?
The mRNA Vaccines and Therapeutics Market is expected to exhibit a CAGR of 8.71% by 2035.
-
Who are the top players in the mRNA Vaccines and Therapeutics Market?
BioNtech, AstraZeneca Plc, Pfizer, Intellia Therapeutics, Crispr Therapeutics, Boehringer Ingelheim, Sangamo Therapeutics, GlaxoSmithKline, Bayer Group, Moderna
-
What was the value of the mRNA Vaccines and Therapeutics Market in 2025?
In 2025, the mRNA Vaccines and Therapeutics Market value stood at USD 5.95 Billion.
Our Clients
